Long-term deprescription in chronic pain and opioid use disorder patients: Pharmacogenetic and sex differences
More than half of patients with opioid use disorder for chronic non-cancer pain (CNCP) reduced their dose through a progressive opioid withdrawal supported by a rotation to buprenorphine and/or tramadol. The aim of this research is to analyse the long-term effectiveness of opioid deprescription taki...
Saved in:
Main Authors: | Muriel Javier, Escorial Mónica, Margarit César, Barrachina Jordi, Carvajal Cristian, Morales Domingo, Peiró Ana M. |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2023-06-01
|
Series: | Acta Pharmaceutica |
Subjects: | |
Online Access: | https://doi.org/10.2478/acph-2023-0018 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol
by: Sergi Mas, et al.
Published: (2025-01-01) -
Editorial: Insights in pharmacogenetics and pharmacogenomics: 2023
by: José A. G. Agúndez, et al.
Published: (2025-01-01) -
Ten-Year Persistence of Biologic Drugs in Psoriasis and Its Relationship with Pharmacogenetic Biomarkers
by: Andrea Rodríguez-Lopez, et al.
Published: (2024-12-01) -
Therapeutic alliance impact on analgesic outcomes in a real-world clinical setting: An observational study
by: Barrachina Jordi, et al.
Published: (2022-12-01) -
Pharmacogenetic markers of colorectal cancer treatment. New approaches for cytostatic drugs efficacy estimation
by: N. B. Zakharzhevskaya, et al.
Published: (2015-12-01)